Global Life Science Leader [ ]
BGI’s unparalleled understanding of its clients’ competitive landscape in conjunction with best-in-class executive through board level recruiting makes it the search firm of choice with clients that are truly focused on driving their success and bringing exceptional shareholder value.
 CEO Board Executive Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Biotechnology Pharmaceutical Medical Device Contract Services Learn More Global Life Science Leader [ ] BGI’s unparalleled understanding of its clients’ competitive
landscape in conjunction with best-in-class executive
through board level recruiting makes it the search firm
of choice with clients that are truly focused on driving
their success and bringing exceptional shareholder value. Saving Lives Improving Treatments Learn More Maximizing Shareholder Value Finding Cures Helping Clients

Encompassing all Executive through Board Positions in Life Sciences

Director of the Board

Yes

Chief Executive Officer

Yes

Chief Business Officer

Leading publicly traded biopharmaceutical stem cell company.

No

Chairman of the Board

Yes

Chief Financial Officer

Formerly Aastrom Biosciences

Yes

Chief Operating Officer

Yes

Chief Scientific Officer

Leading publicly traded monoclonal antibody & oncology company

No

Executive Vice President, Orthopedics and Chief Operating Officer

Formerly BioMimetic Therapeutics, Inc.

Yes
See More

In The News

Injected weight loss drugs remain favored over newer oral treatments by a significant margin, with Eli Lilly’s Zepbound leading the pack, according to a survey of healthcare specialists by Spherix Global Insights.

https://www.fiercepharma.com/pharma/even-launch-obesity-pills-lillys-zepbound-remains-overwhelming-favorite-among-physicians

Fresenius Kabi voluntary recalled one lot of morphine sulfate injection due to a labelling mix-up with prefilled syringes of dilaudid that could trigger an overdose resulting in severe respiratory distress or death.

https://www.fiercepharma.com/manufacturing/fresenius-kabi-recalls-mislabeled-morphine-lot-could-cause-overdose-death

Novo Nordisk has made Omnicom the agency of record for U.S. media buying, ending the drugmaker’s six-year partnership with WPP’s Wavemaker.

https://www.fiercepharma.com/marketing/novo-nordisk-makes-omnicom-agency-record-us-media-buying

AbbVie retook the top spot from rival J&J and its immunology drug Tremfya in July’s top TV drug ad spending rankings.

https://www.fiercepharma.com/marketing/abbvies-skyrizi-back-leading-drug-pharmas-ad-spending-league-july

In a remarkable turnaround, Replimune has reversed the fortune of its melanoma therapy, winning FDA approval after two prior rejections and agency leadership shakeups.

https://www.fiercepharma.com/pharma/replimune-secures-fda-approval-melanoma-therapy-tudriqev-after-long-regulatory-battle

After coming up short with two OX2R agonists, Takeda has scored with oveporexton, gaining FDA approval for the first-in-class drug as a treatment for adults with narcolepsy type 1. Orzeyful, as it will be known commercially, becomes the first medicine to address the root cause of narcolepsy.

https://www.fiercepharma.com/pharma/takeda-gains-fda-nod-first-class-narcolepsy-treatment-orzeyful

Piper Sandler Spring Biopharma Symposium
Boston, MA April 15-16

Needham & Co. Annual Healthcare Conference
New York, NY April 13-16

Society of Gynecologic Oncology Annual Meeting (SGO)
San Juan, Puerto Rico April 11-13

American Academy of Dermatology (AAD)
Denver, CO March 27-30

Society of Toxicology Annual Meeting (SOT)
San Diego, CA March 22-26

American Society of Clinical Oncology Genitourinary Cancers Symposium
San Francisco, CA February 26-28

See More Events

Read More Articles